Novartis France

What Novartis France does

Novartis France is the French subsidiary of Novartis AG, a Swiss-headquartered global pharmaceutical company publicly traded on the NYSE under ticker NVS. Founded in 1996 through the merger of Ciba-Geigy and Sandoz, the French entity operates as a branch/representative office with approximately 516 employees and headquarters in Rueil-Malmaison, Île-de-France. The subsidiary participates across the pharmaceutical value chain, including research, clinical development, commercialization, and patient access, with a portfolio of prescription medicines spanning oncology, immunology, and other therapeutic areas.

The subsidiary operates a Biotechnology Center in Huningue focused on research and biotech development, and historically operated a gene and cell therapy production site (CELLforCURE) in Les Ulis, which was sold to Seqens in November 2023. Novartis France serves two primary customer segments — patients (through access programs, quality commitments, and clinical research participation) and healthcare professionals (via the dedicated Novartis Pro portal, clinical resources, and treatment information). Its go-to-market is sales-led, with direct engagement through field sales into the French healthcare system including hospitals, clinics, and pharmacies.

As a country subsidiary, Novartis France's revenue is not separately disclosed. Pricing is determined through French healthcare system negotiations and insurance reimbursement rather than public pricing. The company is positioned as a research-driven pharmaceutical operator with established regulatory infrastructure, brand heritage dating back 250+ years, and a focus on innovative treatments that improve and extend patient lives. The 2023 divestiture of CELLforCURE signals a strategic narrowing of its manufacturing footprint in advanced therapies while retaining R&D and commercial presence in France.

Name

Novartis France

Legal name

Novartis France (operated by Novartis Pharma)

Website

https://novartis.fr

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Novartis France is the French subsidiary of Novartis AG, commercializing a portfolio of prescription medicines across oncology, immunology, and other therapeutic areas. It serves patients and healthcare professionals through field sales, the Novartis Pro portal, and the French healthcare system, with R&D at its Huningue biotechnology center.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Prescription pharmaceuticals
• Oncology treatments
• Immunology therapies
• Biotechnology research
• Patient access programs

Headquarters

HQ city

Huningue

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Products: Development and commercialization of prescription medicines covering multiple therapeutic areas including oncology, immunology, and other disease treatments

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Novartis France develops and commercializes prescription pharmaceutical products across multiple therapeutic areas including oncology and immunology, operating across the entire medicine value chain from research and biotechnology development to patient access in France. The subsidiary supports healthcare professionals through the Novartis Pro portal and maintains a dedicated Biotechnology Center in Huningue, while prescription medicines are distributed through the French healthcare infrastructure of hospitals, clinics, and pharmacies.

Product overview

Novartis France operates as a pharmaceutical company present across the entire medicine chain. The company offers a portfolio of treatments across therapeutic areas, with dedicated portals for healthcare professionals (Novartis Pro). The organization focuses on patient engagement, access to treatments, clinical research, and quality commitment. Novartis France's activities span research, development, and production, with a specific biotechnology center located in Huningue.

Differentiator

Problem solved

Functional benefit

Brands

• Novartis Pro: Portal dedicated to healthcare professionals

Products and services

• Novartis Pro A dedicated portal for healthcare professionals providing clinical research information, treatment details, and therapeutic area resources for licensed physicians, specialists, and clinical practitioners in France.
• Prescription pharmaceutical products (oncology and immunology therapeutic areas) Prescription medicines covering multiple therapeutic areas including oncology and immunology, developed and commercialized across the French healthcare infrastructure for distribution through hospitals, clinics, and pharmacies.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• SeqensminorStrategic or Co-development Partner · 28 November 2023Novartis completed the sale of CELLforCURE and its gene and cell therapy manufacturing site located in Les Ulis (Essonne) to Seqens. This transaction transferred the production facility operations to Seqens while Novartis continues its pharmaceutical research activities.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• AstraZeneca France: French subsidiary of AstraZeneca, with a strong oncology and immunology pipeline that directly competes with Novartis France's named therapeutic areas in the French market.
• Roche France: French subsidiary of Roche, one of the world's largest oncology-focused pharmaceutical companies. Direct peer to Novartis France given overlapping oncology portfolios and shared go-to-market via French hospitals and specialist prescribers.
• Sanofi: Headquartered in France and the country's largest pharmaceutical company by domestic presence; competes directly with Novartis France across multiple therapeutic areas, with the same sales-led GTM motion targeting French healthcare professionals and the same hospital/pharmacy distribution channels.
• Bayer France: French subsidiary of Bayer, distributing a multi-therapeutic-area branded pharmaceutical portfolio through French hospitals and pharmacies, with overlapping specialty-pharma presence.
• MSD France: French subsidiary of Merck & Co. (MSD), a major oncology and immunology player competing with Novartis France for the same French hospital, pharmacy, and specialist-physician customer base.
• Johnson & Johnson Innovative Medicine France: French pharmaceutical arm of J&J (Janssen), with significant oncology and immunology franchises that overlap with Novartis France's named therapeutic areas and go-to-market approach.
• Eli Lilly France: French subsidiary of Eli Lilly, a major multinational pharmaceutical company with growing oncology and immunology franchises competing with Novartis France in the French specialty market.
• Merck KGaA France: French subsidiary of the Germany-based Merck KGaA, with healthcare operations in oncology, immunology, and neurology — directly overlapping Novartis France's named therapeutic areas.
• GSK France: French subsidiary of GSK, operating across specialty and primary-care pharmaceuticals with overlapping therapeutic areas and the same hospital/clinic distribution channels as Novartis France.
• Pfizer France: French subsidiary of Pfizer, distributing a broad branded prescription portfolio including oncology and immunology products through the same French healthcare system channels as Novartis France.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/novartisfrance

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis France